JP2017075098A - Oral composition for animals, prophylactic agent for periodontal disease for animals using the same and preventive agent for halitosis for animals - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide oral compositions for animals which have a reduced production cost and selectively act on periodontal disease-associated bacteria (mainly Porphyromonas gulae) peculiar to pets such as dogs or cats in particular, by using mastic resin and/or mastic essential oil.SOLUTION: An oral composition for animals exhibiting a bactericidal effect on periodontal disease bacteria comprises mastic resin as an active ingredient.SELECTED DRAWING: None

Description

  The present invention relates to an oral composition for animals containing a mastic resin and / or mastic essential oil as an active ingredient, and particularly to an oral composition effective for pets such as dogs and cats (pets). . Moreover, this invention relates to the periodontal disease preventive agent for animals which uses the said composition for oral cavity for animals, and the bad breath preventive agent for animals.

  In general, in humans, plaque (plaque) adheres as one of the causes of dental caries (caries) and periodontal disease, and removal and prevention, that is, plaque control has been important in oral hygiene. It has been pointed out that there is. The mechanism of plaque formation is that glucosyltransferase, an extracellular enzyme of oral microorganisms, particularly Streptococcus mutans, synthesizes sticky and insoluble glucans using sucrose as a substrate. It consists of forming plaques that adhere to the tooth surface and are agglomerates of bacterial cells.

  As the plaque control method, mechanical plaque removal with a toothbrush or the like, and oral sterilization using an oral bactericidal agent are mainly used. However, in the case of mechanical plaque removal using a toothbrush or the like, plaque cannot be sufficiently removed unless it is performed for a long time with a well-trained and well-polished way. Moreover, if it is the method by a bactericidal agent for oral cavity, since a bactericidal agent component does not osmose | permeate inside with respect to microbial cell aggregates, such as a plaque, the problem that the effect is not fully exhibited. Therefore, it is necessary to devise measures such as increasing the concentration of the bactericide component and increasing the treatment time. In addition, about the plaque removal by the bactericidal agent, since it acts on all the bacteria in the oral cavity, it will also sterilize the oral resident bacteria and bacteria useful for the human body, from the aspect of safety, economy, effectiveness, It was not always satisfactory.

  Periodontal disease in the case of humans is a disease having symptoms that cause inflammation in the periodontal tissues of teeth such as gingivitis, gingivitis, or alveolar pus leakage. Known bacteria that cause periodontal disease include Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Candida. Since periodontal diseases are mainly plaque-derived diseases, plaque control is useful for the prevention as well as for caries prevention, but the same concerns as those described above arise. In addition, some of the periodontal diseases are not derived from plaque, or if they become more severe, professional treatment (mainly chemotherapy with antibiotics, tooth extraction, etc.) is performed at the dental or oral surgery clinic. For example, depending on the administered drug, there is a concern that various gastrointestinal diseases are induced as a side effect.

  In order to eliminate the concerns of caries and periodontal disease prevention in humans as described above, oral compositions with materials that are effective with a small amount of active ingredients and that are easy to handle (eg natural products). Various developments have been made. As an example, an oral composition using mastic (mainly sap thereof) is disclosed in Japanese Patent No. 3389556 (Patent Document 1) and Japanese Patent Application Laid-Open No. 2012-97018 (Patent Document 2). Mastic refers to Pistacia Lentiscus cultivated in Chios Island, Greece, and its sap is mainly used to prevent caries and periodontal disease. Mastic sap is known not only to prevent caries and periodontal disease in humans, but also has antibacterial activity against H. pylori and Campylobacter. The main components of the mastic sap are mastic essential oil, masticadienic acid, isomasticadienic acid, triterpenes, aldehydes, alcohols, poly β-myrcene, and the like.

In addition, Lactobacillus brevis (Lactobacillus), a kind of plant lactic acid bacteria, is also effective as a composition for oral cavity that is effective with a small amount of active ingredients and is easy to handle.
An oral composition mainly using brevis) bacteria is disclosed in Japanese Patent Application Laid-Open No. 2014-166992 (Patent Document 3). The plant lactic acid bacteria used in Patent Document 3 have a body length of about 0.1 to 5 μm and are used as dead bacteria. As a result, an oral composition having a small content and reduced production cost is provided.

  By the way, prevention of dental caries and periodontal disease is indispensable also in non-human animals, especially pets (pets) such as dogs and cats. In pet animals, like humans, chemical treatment is performed by mechanical plaque control using a toothbrush performed by an owner or the like, and mouth washing using a periodontal disease preventive or therapeutic agent for animals. In addition, treatments with pet foods and chewing gums mixed with these therapeutic agents, medications, and preventive treatments by vaccine administration are performed. By the way, depending on the living environment, there are common causes of periodontal disease in dogs and cats, such as Porphyromona gingivalis and Prevotella intermedia. . However, teeth that parasitize dogs and cats, such as Porphyromonas.gulae, Porphyromonas.salivosa, and Odoribacter.denticanis, which do not exist in humans. There are also causative bacteria of peri-illness.

  For example, Japanese Patent No. 4099213 (Patent Document 4) discloses a preventive vaccine against Porphyromonas. Gulae, which is a causative agent of periodontal disease infesting dogs and cats. Further, as an oral composition for Porphyromonas. Gulae and the like, an oral composition derived from the extract of tomorrow is disclosed in JP-A-2015-67539 (Patent Document 5).

Japanese Patent No. 3389556 JP 2012-97018 A JP 2014-166992 A Japanese Patent No. 4099213 Japanese Patent Laying-Open No. 2015-67539

  However, Patent Documents 1, 2 and 3 are intended only for humans and, for example, show effective effects on Porphyromonas gingivalis, but Porphyromonas gulae (Porphyromonas.gulae), porphy For the causative bacteria of periodontal disease that parasitize dogs and cats such as Porphyromonas. Salivosa and Odoribacter. Denticanis, there are descriptions and suggestions showing such effects. Absent.

  Moreover, in the invention which concerns on patent document 4, vaccine administration is main and there is no direct description, However, The treatment by a veterinarian is required. In other words, there is no description or suggestion that owners who do not have veterinary qualifications can care for pets such as dogs and cats. Of course, Patent Document 4 does not have a description or suggestion of using mastic as in Patent Documents 1 and 2, and a description or suggestion of using plant lactic acid bacteria as in Patent Document 3.

  And in patent document 5, dosage forms, such as a paste and a gel, are taken so that an owner can handle easily. There is also a statement that mastic is used. In view of this, an oral composition for animals based on the knowledge of Patent Documents 1 to 5 can be considered.

  However, in Patent Document 5, tomorrow leaf extract is only an active ingredient for Porphyromonas gulae (Porphyromonas. Gulae). And it was mentioned above that there is a statement that mastic is used, but it is only used as a fragrance and is a causative agent of periodontal disease that parasitizes dogs and cats (especially Porphyromonas. Gulae) On the other hand, there is no description or suggestion that mastic is effective.

  In view of the above circumstances, the present invention can reduce the manufacturing cost by using a mastic resin and / or mastic essential oil, and in particular a periodontal disease-related bacterium (especially porphyro) peculiar to pets such as dogs and cats. An object of the present invention is to provide a veterinary composition for animals having an effect on Monphys glae (Porphyromonas. Gulae).

  The above-described object of the oral composition for animals according to the present invention is an oral composition for animals having a bactericidal effect against periodontal disease bacteria, and is achieved by containing a mastic resin as an active ingredient. The

  In addition, the above object of the animal oral composition according to the present invention is to use the mastic resin as a mastic resin solution having a concentration of 5 to 60%, or the mastic resin solution is a solvent. Solvents for dissolving the mastic resin as well as ethanol, glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglycerides (8 to 18 carbon atoms for fatty acid-derived moieties) tri (caprylic acid) / Glyceryl capric acid, fatty acid monoglyceride (8-18 carbon atoms for fatty acid-derived moieties), glyceryl monocaprate, fatty acid ester (8-18 carbon atoms for fatty acid-derived moieties), isopropyl myristate, ethyl isooctanoate, myristine Octyldodecyl acid, higher alcohol (carbon number -22), oleyl alcohol, sorbitan fatty acid (8 to 18 carbon atoms for fatty acid-derived parts) ester, or sucrose fatty acid ester (8 to 18 carbon atoms for fatty acid-derived parts) Or the content of the mastic resin liquid is 0.1 to 50%, or further contains mastic essential oil as an active ingredient, or the content of the mastic essential oil is 0. It is 01 to 1.0%, or further contains a lactic acid bacterium whose mode value in the particle size distribution is 1.0 μm or less as an active ingredient, or the lactic acid bacterium is at least one of Lactobacillus bacteria Or the Lactobacillus bacteria are dead or When the strain of the lactic acid bacterium is Lactobacillus brevis strain BP-4693, or the content of the lactic acid bacterium is 0.01 to 1.0%, or the target animal is a dog or a cat Or by the fact that the periodontal disease bacteria is Porphyromonas. Gulae.

  Moreover, this invention is effectively achieved also by the periodontal disease preventive agent for animals which uses the said composition for oral cavity for animals, or the bad breath preventive agent for animals.

  According to the composition for oral cavity for animals according to the present invention, the use of a mastic resin and / or mastic essential oil can reduce the production cost, and in particular, it relates to periodontal diseases peculiar to pets such as dogs and cats. It has been shown to act on bacteria (especially Porphyromonas. Gulae).

  Further, depending on the dosage form, the use of the animal oral composition according to the present invention enables application to an animal periodontal disease preventive agent or an animal bad breath preventive agent.

  Hereinafter, the composition for oral cavity for animals concerning the present invention is explained in detail. In the present application, “mastic sap” refers to sap obtained from Pistacia lentiscus of the Urushi family, and as described above in the background section, the main components are masticadienic acid, isomasticadienic acid, triterpene. Aldehydes, alcohols, poly-β-myrcene and the like. “Mastic resin” means a mastic sap that has been naturally dried and solidified. “Mastic essential oil” refers to a product obtained by refining volatile components (mainly terpenes) from mastic sap or mastic resin by steam distillation or dry distillation. In addition, “%” is a percentage by weight unless otherwise specified.

  First, the mastic resin will be described. The mastic resin is an important component that exhibits an antibacterial action against periodontal disease related bacteria (particularly Porphyromonas. Gulae) in the oral composition for animals according to the present invention. As described above, the mastic resin is obtained by naturally drying mastic sap. Incidentally, the time for natural drying is not particularly limited as long as it is one day or longer.

  In the composition, a mastic resin is used by dissolving in a solvent. The reason for dissolving in the solvent is that the mastic resin itself is insoluble in water, and the result of examining the compatibility with various additives when the composition takes various dosage forms such as gel and liquid. is there.

  As a solvent for dissolving the mastic resin, ethanol, glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglyceride (about 8 to 18 carbon atoms for the fatty acid-derived portion, especially 8 to 12 carbon atoms) Glyceryl tri (caprylic acid / capric acid), fatty acid monoglyceride (the fatty acid-derived part has about 8 to 18 carbon atoms, among which 8 to 12 carbon atoms are desirable), glyceryl monocaprate, fatty acid Esters (the fatty acid-derived portion has about 8 to 18 carbon atoms, preferably those having 8 to 12 carbon atoms), isopropyl myristate, ethyl isooctanoate, octyldodecyl myristate, higher alcohol (about 8 to 22 carbon atoms) ), Oleyl alcohol, sorbitan fatty acid Steal (about 8 to 18 carbon atoms for fatty acid-derived parts, especially those having 8 to 12 carbon atoms are desirable), sucrose fatty acid esters (about 8 to 18 carbon atoms for fatty acid-derived parts, especially 8 carbon atoms) ~ 12 are desirable.) Etc. can be used.

  In addition, what is necessary is just to make it become a homogeneous solution with respect to a solvent, when using a mastic resin for the composition for oral cavity for animals which concerns on this invention. Hereinafter, this homogeneous solution is referred to as “mastic resin liquid”. The concentration of the mastic resin liquid is desirably 5 to 60%. Incidentally, when the concentration is 5% or less, an antibacterial effect against Porphyromonas. Gulae cannot be obtained, and when the concentration is 60% or more, a heterogeneous solution is formed. The bactericidal effect against Porphyromonas glae is also less than when it is less than 5%.

  About the preparation method of a mastic resin liquid, if the said density | concentration is observed, it may be a conventional method. The melting temperature of the mastic resin may be appropriately increased in consideration of the boiling point of the solvent and the like, and may be room temperature depending on the case. It is desirable that the mastic resin is dissolved in a solvent and then filtered to be used as a mastic resin liquid.

  The content of the mastic resin solution is preferably 0.1 to 50% with respect to the total amount of the oral composition for animals according to the present invention. By the way, when converted as mastic resin itself, if the content of the mastic resin liquid is 0.1% or less, the bactericidal effect against Porphyromonas. Gulae decreases or the bactericidal effect thereof Is not shown. In addition, if the content of the mastic resin liquid is 50% or more, there is a concern that even if the bactericidal effect against Porphyromonas grae is sufficient, the tissue around the affected area in the pet causes some kind of inflammation or allergic reaction. In some cases, the bactericidal effect against Porphyromonas. Gulae may be lower than within this concentration range.

  Next, the mastic essential oil will be described. By the way, as for the mastic essential oil, as described above, a mastic sap or a resin obtained by steam distillation or dry distillation to refine volatile components (mainly terpenes) may be used. It should be noted that conventional methods may be used for refinement.

  The content of the mastic essential oil is desirably 0.01 to 1.0% with respect to the total amount of the oral composition for animals according to the present invention. If the content of the mastic essential oil is 1.0% or more, the tissue around the affected area in the pet may cause some inflammation or allergic reaction as in the case of the mastic resin liquid, and in some cases May reduce the bactericidal effect on Porphyromonas. Gulae. Incidentally, about mastic essential oil, even if it is not contained in the oral composition for animals according to the present invention, that is, mastic resin alone shows a bactericidal effect against Porphyromonas gulae (Porphyromonas.gulae) If this is done, a better bactericidal effect can be obtained. In addition, the addition of mastic essential oil plays a role in preventing bad breath. In addition, it is because a bad breath prevention effect is not shown as content of mastic essential oil is 0.01% or less.

  And the composition for oral cavity for animals which concerns on this invention is materialized by containing the lactic acid bacteria whose mode value in a particle size distribution is 1.0 micrometer or less as an active ingredient further. The “mode value in the particle size distribution” referred to here is a value serving as an index representing the size (body length) of the bacteria, and the relative frequency in the particle size distribution when the particle diameter (body length) of the cells is measured. The maximum particle size. In other words, when “mode is 1.0 μm or less”, the length of the microbial cell is in the range of 0.1 to 5 μm. Incidentally, the length of the bacterial cell can be measured by a known technique such as an electron microscope. When the mode value is 1.0 μm or more, it shows a life-and-death effect against Porphyromonas. Gulae, but the number of uptake by the bacteria rapidly decreases. It is desirable to use it at 0 μm or less. In addition, what is necessary is just to prepare about the lactic acid bacteria used by this invention by a well-known technique (for example, refer international patent publication 2009/157073).

  Lactic acid bacteria used in the oral composition for animals according to the present invention include Lactobacillus brevis, L. brevis subspecies coagulans, Lactobacillus acidophilus (L .acidphilus), Lactobacillus gaseri (L.gasseri), Lactobacillus mari (L.mali), Lactobacillus plantarum (L.plantarum), Lactobacillus buchneri (L.buchneri), Lactobacillus casei ( L. casei), Lactobacillus johnsonii, L. gallinarum, L. amylovorus, L. rhamnosus, Lactobacillus kefir (L.kefir), Lactobacillus paracasei, Lactobacillus crispata Lactobacillus bacteria such as L. crispatus, Lactococcus lactis bacteria such as Lactococcus lactis, Enterococcus faecalis, Enterococcus faecium bacteria such as E. faecium Bifidobacterium bifidum, B. longum, B. adolescentis, B. infantis (B.infantis) ), Bifidobacterium breve (B. breve), Bifidobacterium catenulatum (B. catenulatum) and the like. Among these, bacteria belonging to the genus Lactobacillus are preferred, and among these, the strain BP-4663 of L. brevis is preferred. The lactic acid bacteria are preferably dead bacteria. This is because when preparing as a lactic acid bacterium used in the present invention, the preparation is easy, and even a dead bacterium sufficiently exhibits a desired bactericidal effect.

  Moreover, it is preferable to contain the said lactic acid bacteria 0.01 to 1.0% with respect to the whole quantity of this oral composition for animals in the oral composition for animals which concerns on this invention. If it is less than 0.01%, lactic acid bacteria do not exhibit the effect of killing Porphyromonas. Gulae. Moreover, when it is 1.0% or more, the uptake number of the bacteria is affected.

  The dosage form of the animal oral composition of the present invention is selected from toothpastes, gels, liquid toothpastes, powdered toothpastes, mouthwashes, films, chewing gums, pet food additives, or pasta. Can be done.

  In addition, under the same blending conditions as the animal oral composition of the present invention, an animal periodontal disease preventive agent and animal bad breath preventive agent can be obtained.

  In the embodiment described above, the composition for oral cavity for animals according to the present invention, the preventive agent for periodontal disease for animals and the preventive agent for bad breath for animals using the composition can be implemented. An additive may be included. The additive will be described next.

  As an example of the additive, the composition for oral cavity for animals according to the present invention is formed by further adding papaya extract and / or chitosan. These show synergistic effects with the lactic acid bacteria described above.

  Papaya extract is an extract derived from natural papaya fruit. It is an extract obtained by crushing the natural papaya fruit and immersing it in a solvent such as ethanol. The papaya fruit is still blue even if it is ripe. It may be in an incomplete state. This papaya extract plays a role as a wetting agent, can keep the moisture in the oral cavity, and particularly unripe papaya is rich in papain enzymes. This papain enzyme makes it easier to remove plaque on the tooth surface and between the teeth and gums, and the effect of killing Porphyromonas. Gulae by lactic acid bacteria is more exhibited. Although the compounding quantity of this papaya extract is not specifically limited, 0.005%-10% are desirable with respect to the whole quantity of the composition for oral cavity which concerns on this invention. If it is less than 0.005%, the above-mentioned effect is not exhibited, and if it exceeds 10%, the effect of lactic acid bacteria on Porphyromonas. Gulae may be diminished.

  On the other hand, chitosan is obtained by boiling chitin obtained from crustacean exoskeletons such as crabs and shrimps by boiling treatment with strong alkali or the like. Since it is a polysaccharide, it may be used as a binder, but it also has an effect of showing an antibacterial agent and a tooth surface coating action. Moreover, the above-mentioned lactic acid bacteria or papain enzyme can be kept on the tooth surface for a longer time. Thereby, the effect of killing and activating Porphyromonas. Gulae is more exhibited. Although the compounding quantity of this papaya extract is not specifically limited, 0.005%-10% are desirable with respect to the whole quantity of the composition for oral cavity which concerns on this invention. If it is less than 0.005%, the above-mentioned effect is not exhibited, and if it exceeds 10%, the effect of lactic acid bacteria on Porphyromonas. Gulae may be diminished.

  Furthermore, you may mix | blend chitosan and a papaya extract simultaneously. As a result, the chitosan can lengthen the time for the papain enzyme and lactic acid bacteria to stay in the tooth surface or between the teeth and gums, combined with the bactericidal effect by chitosan, and the effect of killing Porphyromonas gae (Porphyromonas.gulae) Is more effective. The blending amount in this case is not particularly limited, but 0.005% to 10% is preferable for each of chitosan and papaya extract. If it is less than 0.005%, the above-mentioned effect is not exhibited, and if it exceeds 10%, the effect of lactic acid bacteria on Porphyromonas. Gulae may be diminished.

  Silica-based abrasives such as silica gel, precipitated silica, additive silica, hydrous silicic acid, silicic anhydride, zeolite, aluminosilicate, zirconosilicate, crystalline cellulose, dicalcium phosphate dihydrate, second Anhydrous calcium phosphate, calcium pyrophosphate, tribasic magnesium phosphate, tribasic calcium phosphate, aluminum hydroxide, alumina, light calcium carbonate, heavy calcium carbonate, magnesium carbonate, zirconium silicate, synthetic resin abrasive and the like. Among these, one kind or two or more kinds can be used in combination. As for the compounding quantity of these abrasive | polishing agents, 0 to 60% is common with respect to the oral cavity composition whole quantity which concerns on this invention.

  Examples of the wetting agent include polyhydric alcohols such as glycerin, concentrated glycerin, diglycerin, sorbitol, maltitol, dipropylene glycol, propylene glycol, 1,3-butylene glycol, xylitol, polyethylene glycol, and one or two of these. The above can be used. These can also be used as a solvent for dissolving the mastic resin.

  As a binder (thickener), carrageenans, alginic acid, sodium alginate, propylene glycol alginate, calcium-containing sodium alginate, potassium alginate, calcium alginate and its derivatives such as alginic acid and its derivatives, xanthan gum, guar gum, gelatin, agar, Examples thereof include sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium polyacrylate, pullulan and the like, and one or more of these can be used in combination. The thickener also serves as a gel (gel) agent.

  N-acyl amino acid salts such as sodium lauryl sulfate, sodium lauroyl sarcosine, sodium alkylsulfosuccinate, sodium coconut oil fatty acid monoglycerin sulfonate, sodium α-olefin sulfonate, N-acyl glutamate, 2-alkyl-N- Carboxymethyl-N-hydroxyethylimidazolinium betaine, maltitol fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, fatty acid diethanolamide, polyoxyethylene sorbitan monostearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid An ester etc. are mentioned, These 1 type (s) or 2 or more types can be used together.

  As pH (hydrogen ion concentration) adjusting agents, citric acid, citric acid (mono or di) sodium, malic acid, malic acid (mono or di) sodium, gluconic acid, gluconic acid (mono or di) sodium, succinic acid, succinic acid Examples thereof include sodium, lactic acid, sodium lactic acid (mono or di), potassium carbonate, sodium hydrogen carbonate and the like, and one or more of these can be used in combination.

  As a retention agent for retaining (sustaining) the active ingredient of the veterinary composition for animals according to the present invention, liquid paraffin, liquid hydrocarbon paraffin and polyethylene gelled hydrocarbon, vegetable oil, beeswax and the like can be used, These can be used alone or in combination of two or more. The gelled hydrocarbon also serves as a gelling agent.

  Sweeteners include sodium saccharin, aspartame, trehalose, stevioside, stevia extract, p-methoxycinnamaldehyde, neohesperidyl dihydrochalcone, perilartin, xylitol and the like.

  Examples of preservatives include parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, sodium benzoate, phenoxyethanol, and alkyldiaminoethylglycine hydrochloride.

  As a fragrance component, one or more of l-menthol, anethole, menthone, cineol, limonene, carvone, methyl salicylate, ethyl butyrate, eugenol, thymol, cinnamaldehyde, trans-2-hexenal, etc. Can do. Although these components may be blended as a single product, an essential oil containing them may be used.

  Incidentally, the compounding amount of each component such as the wetting agent, binder, foaming agent, retention agent, sweetener, preservative, and fragrance component described above is not particularly limited, but it is the total amount of the oral composition for animals. On the other hand, the range of 0.001 to 20% is common.

  In addition to the above fragrance components, fragrance components such as aliphatic alcohols and esters thereof, terpene hydrocarbons or terpene alcohols, phenol ethers, aldehydes, ketones, lactones, and essential oils are blended within a range that does not interfere with the effects of the present invention. May be. The blending amount of the fragrance is generally in the range of 0.001 to 20% with respect to the total amount of the oral composition for animals according to the present invention.

In addition to the above, the animal oral composition of the present invention may further contain an active ingredient. Such active ingredients include lysozyme chloride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, potassium nitrate, sodium polyphosphate, polyethylene glycol, polyvinyl pyrrolidone, hinokitiol, ascorbic acid (vitamin C), ascorbates, chlorhexidine salts , Cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, bisabolol, triclosan, isopropylmethylphenol, tocopherol, tocopherol acetate, ε-aminocaproic acid, tranexamic acid, aluminum hydroxyl allantoin, aluminum lactate, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizinate , Copper chlorophyllin salt, sodium chloride, guaiazulene sulfonate, dextra Over Ze, pyridoxine hydrochloride, and the like medicinal hydroxyapatite, it is possible to formulate one or more kinds thereof. About this active ingredient, the range of 0.001 to 20% with respect to the total amount of the oral composition according to the present invention is common.
Then, the numerical values described above for the mastic resin (however, as a mastic resin liquid), mastic essential oil, lactic acid bacteria, additives, etc. with respect to the total amount of the oral composition for animals according to the present invention. When mixed in a range, the remainder may be used as a solvent (for example, a solvent in which a mastic resin is dissolved), a gelling agent, or the like. Further, the additive can also be applied to an animal periodontal disease preventive or halitosis preventive agent by the same formulation as the animal oral cavity composition of the present invention.

  The composition for oral cavity for animals of this invention can be manufactured according to a conventional method, The manufacturing method is not specifically limited.

  In addition, regarding the oral composition for animals of the present invention, various aspects have been described in the case of Porphyromonas. Gulae, but periodontals that are resident in mammals other than humans are described. It seems to be effective against pathogens such as Porphyromonas. Salivosa and Odoribacter.denticanis.

  Moreover, in the composition for oral cavity for animals of the present invention, the embodiment has been described for animals other than humans, that is, dogs or cats, but it is also used for rabbits, hamsters, guinea pigs, etc. that are pets as pets. Is possible.

  Although the embodiment of the veterinary composition for animals according to the present invention has been described above, the present invention is not limited to the above-described embodiment, and within the scope of the claims and the description of the present specification, It goes without saying that various modes can be adopted.

  In order to support the above embodiment of the composition for oral cavity according to the present invention, examples will be further described. Examples described here include mastic resin, mastic essential oil, which are constituents of the composition for oral cavity for animals according to the present invention, and lactic acid bacteria whose mode value in particle size distribution is 1.0 μm or less (hereinafter referred to as the present invention). In the Examples, the counteracting effect of periodontal disease bacteria (in this example, P. gulae) of “nano-type lactic acid bacteria” was examined.

[Preparation Example 1] Preparation of mastic resin liquid and mastic essential oil First, sap collected from Pistacia lentiscus (hereinafter referred to as "Mastic sap") from Chios, Greece Dried. After drying, it was separated into a volatile component and a resinous substance by steam distillation, and the resinous substance was used as the “mastic resin” used in the examples of the present application. On the other hand, the volatile component was further refined after isolation by steam distillation to obtain “Mastic essential oil” used in this example. In addition, the conventional method was followed about refinement | pulverization.

  Next, for the mastic resin, the solvent was tri (caprylic acid / capric acid) glyceryl to obtain a 30% concentration solution. The obtained solution was designated as “mastic resin solution” used in this example.

[Preparation Example 2] Preparation of nano-type lactic acid bacteria Nano-type lactic acid bacteria used in this example were prepared according to International Patent Publication No. 2009/157073.

  First, as a lactic acid bacterium, a Lactobacillus brevis bacterium (strain BP-4693, hereinafter simply referred to as “brevis bacterium”), which is a plant lactic acid bacterium, is used, and the brevis bacterium is a known nutrient with 5% glucose added. Use 20% aqueous sodium hydroxide solution in the medium and adjust the pH (hydrogen ion concentration) during cultivation to 6.5 while culturing at 36.5 ° C. When the consumption of glucose (glucose) is completed It was.

  After completion of the culture, the culture solution is sterilized by heating at 80 ° C. for 10 minutes, and the cells are washed with PBS (phosphate buffer solution). A sample was prepared by adding and dispersing with a mixer, followed by lyophilization. The sample was again suspended in PBS so that the cell concentration was 10 mg / mL. In addition, what was hold | maintained at pH 6.5 at the time of a process process was made into the nano type | mold lactic acid bacteria (brevis bacteria) used by a present Example. Furthermore, the nano-type lactic acid bacteria were heat-treated to make dead bacteria.

  Incidentally, when the particle size of the prepared nano-type lactic acid bacteria was measured, it was 0.7 to 1.0 μm or less for all the cells, and the mode value of the particle size distribution was 1.0 μm or less. In addition, the particle size measurement depended on a conventional method.

[Adjustment Example 3] Preparation of Diluents for Mastic Resin Liquid, Mastic Essential Oil, and Nano-type Lactic Acid Bacteria Further, for mastic resin liquid, mastic essential oil, and nano-type lactic acid bacteria used in this example, a solvent is used. Each was diluted as tri (caprylic / capric) glyceryl. Specifically, the mastic resin solution was diluted 10 times, and the mastic essential oil and the nano-type lactic acid bacteria were each diluted 1000 times. Hereinafter, in this example, they are referred to as “mastic resin dilution liquid”, “mastic essential oil dilution liquid”, and “nano-type lactic acid bacteria dilution liquid”, respectively. Use a sterilized test tube for dilution. Each dilution was prepared at the time of use.

[Adjustment Example 4] Preparation of test solution for anti-periodontal disease bacteria effect test As a typical example of the test solution for anti-periodontal disease bacteria effect test according to this example (sometimes simply referred to as "test solution"), it will be described later. The test liquid according to Example 8 will be described as an example. In Example 8, “mastic resin solution 3.00%, mastic essential oil 0.03%, nano-type lactic acid bacteria 0.01%” (see Table 2) (in this case, one sterilized bottle) In the test tube, 2.7 mL of the mastic resin diluent prepared in Preparation Example 3, 2.7 mL of the mastic essential oil diluent and 1.0 mL of the nano-type lactic acid bacteria dilution solution, and tri (caprylic acid / capric acid) glyceryl 2. 6 mL was added to make a total volume of 9 mL. By the way, the order of mixing is not particularly relevant.

  Incidentally, in each of the examples described later (see Tables 1 to 4), the amount of each diluting solution and tri (caprylic acid / capric acid) glyceryl is determined as follows. The concentration can be appropriately changed according to each concentration of mastic essential oil and nano-type lactic acid bacteria.

  Further, the test solution in the control test (comparative example, see Tables 1 to 4) is only tri (caprylic acid / capric acid) glyceryl without mixing the mastic resin solution, mastic essential oil and nano-type lactic acid bacteria. Details will be described later.

  In addition, the test solutions according to each Example and Comparative Example are also prepared at the time of use.

[Preparation Example 5] Preparation of Periodontal Disease Bacterial Solution As a periodontal disease bacteria used in this example, a dog periodontal disease causative organism, Porphyromonas grae (P. gulae) is selected, JCM13865 ^T was used.

The strain was anaerobically cultured on a blood agar medium at 37 ° C. for 5 days. After culturing, an appropriate amount of the grown colonies were collected with a platinum loop and suspended in sterilized physiological saline and McFarland turbidity standard solution (No. 1). The suspension is referred to as “periodontal disease bacterial solution” used in this example. In addition, the number of bacteria in the periodontal disease bacterial solution was approximately 1 to 3 × 10 ⁸ CFU / mL. Incidentally, the periodontal disease bacterial solution was prepared at the time of use.

[Example] Anti-periodontal disease bacteria effect test Test solution for anti-periodontal disease effect test according to each Example and each comparative example prepared in Preparation Example 3, and periodontal disease prepared in Preparation Example 5 (P. gulae) ) The test was conducted using the bacterial solution.

  First, the test solution according to each example will be described. In Examples 1 to 4, the mastic resin solution is fixed at 10.0%, the mastic essential oil (concentration is fixed at 0.03%), and the nano-type lactic acid bacteria (concentration is fixed at 0.01%). The variation of each is changed. In Examples 5 to 8, the mastic resin solution is fixed at 3.0%, the mastic essential oil (concentration is fixed at 0.03%) and the nano-type lactic acid bacteria (concentration is fixed at 0.01%). The variation of each is changed. In Examples 9 to 12, the mastic resin solution is fixed to 1.0%, the mastic essential oil (concentration is fixed to 0.03%) and the nano-type lactic acid bacteria (concentration is fixed to 0.01%). The variation of each is changed. In "Examples 13 to 16," the mastic resin solution was fixed to 0.5%, mastic essential oil (concentration fixed to 0.03%) and nano-type lactic acid bacteria (concentration fixed to 0.01%) The variation of each is changed. In addition, the preparation of the test solution according to each example is prepared at the time of use by the method as shown in the above-mentioned Preparation Example 3.

  Next, each comparative example will be described. “Comparative Example 1” is a control experiment of Examples 1 and 2, “Comparative Example 2” is a control experiment of Examples 3 and 4, and “Comparative Example 3” is a control experiment of Examples 5 and 6. “Comparative Example 4” is a control experiment of Example 7, “Comparative Example 5” is a control experiment of Example 8, “Comparative Example 6” is a control experiment of Example 9, “Comparative Example 7”. "As a control experiment of Example 10," Comparative Example 8 "as a control experiment of Examples 11 and 12," Comparative Example 9 "as a control experiment of Examples 13 and 14," Comparative Example 10 " Were tested as control experiments in Examples 15 and 16, respectively.

  Next, the anti-periodontal disease bacteria effect test will be described. Briefly, with respect to 9 mL of the test solution according to each example, the time when 1 mL of the periodontal disease (P. gulae) bacterial solution was added was defined as the action time of 0 minutes, and the Porphyromonas grae (P. gulae) over time. The number of bacteria is measured. Next, a specific description will be given.

  First, 1 mL of the mixed solution was sampled with a pipette at the time when 1 mL of the periodontal disease bacterial solution was added to 9 mL of the test solutions according to Examples 1 to 16, respectively. About the collected mixed solution, 9 mL of sterilized physiological saline was added and stirred, and 10-fold serial dilution was performed by repeating this. 0.1 mL of what was considered to be an appropriate dilution stage was collected and smeared on two blood agar media. After the smearing, each medium was subjected to anaerobic culture at 37 ° C. for 5 days, after which the number of colonies in each medium was counted, and Porphyromonas glae (P .gulae) was counted.

  Under the same conditions, the Porphyromonas glaue (P) after 5 minutes, 10 minutes, 15 minutes and 30 minutes after the test solution according to Examples 1 to 16 and the periodontal disease bacterial solution were allowed to act. .gulae) was counted. However, 5 minutes after the action time in Example 7, 5 minutes after the action in Example 9, and 30 minutes after the action in Example 11 were not measured for convenience (Tables 2 and 3 described below). reference).

  After the above-mentioned count of bacteria, in Examples 5 to 8, 0 minutes, 5 minutes, 10 minutes, 15 minutes and 30 minutes after the test solution and periodontal disease bacterial solution were allowed to act under the same conditions. The number of bacteria of each P. gulae was measured again (second time). However, after the above-mentioned bacterial count measurement, in Examples 1 to 4, 0 minutes, 1 minute, 3 minutes, and 5 minutes after applying the test solution and periodontal disease bacterial solution under the same conditions, respectively. A second measurement was made of the number of P. gulae bacteria. In addition, regarding Examples 9 to 16, re-measurement for the number of P. gulae bacteria was not performed (see Tables 3 and 4 described later).

  Next, for Comparative Examples 1 to 10, without mixing the mastic resin solution, mastic essential oil, and nano-type lactic acid bacteria, 1 mL of periodontal disease bacterial solution for 9 mL of tri (caprylic acid / capric acid) glyceryl alone The number of bacteria of P. gulae was counted under the same dilution conditions, medium conditions, and action time as in each Example, with the time of addition of 0 being the action time of 0 minutes.

  Tables 1 to 4 show changes in the number of bacteria of P. gulae according to Examples 1 to 16 and Comparative Examples 1 to 10.

  First, Table 1 will be described. Table 1 shows examples of Porphyromonas glae (P. gulae) when Examples 1 to 4, i.e., the mastic resin solution was fixed at 10%, and the variations of mastic essential oil and nano-type lactic acid bacteria were changed, respectively. It is a measurement result of the number of bacteria. In addition, about the number of bacteria, it converts into the common logarithm so that the number of digits of the number of bacteria becomes clear.

  In Comparative Example 1, the number of bacteria decreased by almost an order of magnitude or almost constant over time, that is, the number did not change much, whereas Example 1 and 10% mastic resin solution alone showed only 10% mastic resin solution. In Example 2 using a stick resin solution and 0.03% of mastic essential oil, the number of instantaneous digits applied was reduced by about 4 (log [CFU / mL] = After about 5 minutes, it became below the measurement range limit (log [CFU / mL] <3.5). And in Example 1 and 2, when the number of bacteria was measured again, it turned out that it will become a measurement range limit in 3 minutes of action time (refer Table 1 "2nd time").

  Next, in Comparative Example 2, the number of bacteria decreased by an order of magnitude or almost the same as in Comparative Example 1, that is, the number did not change so much, whereas the 10% mastic resin solution and nano-type lactic acid bacteria 0. In Example 3 using 01% and Example 4 using 10% mastic resin solution, mastic essential oil 0.03% and nano-type lactic acid bacteria 0.01%, the action time was 5 to 10 minutes in the first measurement. It became below the measurement range limit (log [CFU / mL] <3.5). And in Example 3 and 4, when the number of bacteria was measured again, it turned out that the number of bacteria decreases gradually in 5 minutes of action time unlike the case of Example 1 and 2 (Table 1 "2nd time"). reference).

  From this, when Examples 1 to 4, that is, when the mastic resin solution is 10%, it is possible to use Porphyromonas glae (P) by itself or when mixed with mastic essential oil and / or nano-type lactic acid bacteria. The number of .gulae) tends to decrease, and it was found that the measurement range limit (log [CFU / mL] <3.5) is certainly below 30 minutes after 30 minutes.

  Next, Table 2 will be described. Table 2 shows Examples 5 to 8, that is, P. gulae (P. gulae) obtained by fixing the mastic resin solution to 3.0% and changing the variations of the mastic essential oil and the nano-type lactic acid bacteria, respectively. ) Count of bacteria. Note that the number of bacteria is converted to a common logarithm as in Table 1 so that the number of bacteria is clear.

  In Comparative Example 3, as the time passed, the number of bacteria decreased by an order of magnitude or almost constant, that is, the number did not change much, while Examples 5 and 3 using only 3.0% mastic resin solution. In Example 6 using 0.0% mastic resin solution and 0.03% essential oil, the number of instantaneous digits applied decreased by about 2.5 (before the test solution and periodontal fungus solution were applied, [CFU / mL] = about 8) After 10 minutes, the measurement range became less than the limit of the measurement range (log [CFU / mL] <3.5). Then, in Examples 3 and 4, when the number of bacteria was measured again (second time), it was found that the action time was 15 minutes or less almost at the measurement range limit, and after 30 minutes both were below the measurement range limit. (See Table 2, “Second time”).

  Next, in Comparative Examples 3 and 4, the number of bacteria was reduced by almost an order of magnitude or almost the same as in the other Comparative Examples, that is, the change in the number was not so much. In Example 7 using nano-type lactic acid bacteria 0.01% and Example 8 using 3.0% mastic resin solution, mastic essential oil 0.03% and nano-type lactic acid bacteria 0.01%, Was almost below the measurement range limit (log [CFU / mL] <3.5) after 30 minutes of action. However, when the number of bacteria was measured again in Examples 7 and 8, unlike in Examples 5 and 6, after 10 minutes of action time, the measurement range limit was gradually increased (log [CFU / mL] <3.5). It turned out that it became the following (refer Table 2 "2nd time").

  From this, when Examples 5 to 8, that is, when the mastic resin solution was 3.0%, either Porphyromonas glae itself or when mixed with mastic essential oil and / or nano-type lactic acid bacteria were used. The number of (P. gulae) bacteria tends to decrease, and among them, as shown in Example 8, the mastic resin solution, the mastic essential oil, and the nano-type lactic acid bacteria are more reliable than the examples 5 to 7. It was found that the measurement range limit (log [CFU / mL] <3.5) was reached after a minute.

  Next, Table 3 will be described. Table 3 shows Examples 9 to 12, that is, P. gulae when the variation of mastic essential oil and nano-type lactic acid bacteria was changed by fixing the mastic resin solution to 1.0%. ) Count of bacteria. In addition, about the number of bacteria, like Table 1 and Table 2, it converts into the common logarithm so that the number of digits of the number of bacteria becomes clear.

  In Comparative Examples 6 and 7, the number of bacteria decreased by almost an order of magnitude or almost constant with time, that is, the number did not change much, whereas Example 9 with only 1.0% mastic resin solution. In Example 10 using 1.0% mastic resin solution and 0.03% essential oil, log [CFU / mL]> 5.5 even if the number of bacteria was almost constant or decreased.

  Next, in Comparative Example 8, the number of bacteria was reduced by almost an order of magnitude or almost the same as in the other Comparative Examples, that is, the change in the number was not so much, whereas the 1.0% mastic resin solution and the nano type In Example 11 using 0.01% lactic acid bacteria and Example 12 using 1.0% mastic resin solution, 0.03% mastic essential oil and 0.01% nano-type lactic acid bacteria, In comparison, the number of bacteria decreased slightly.

  Therefore, in Examples 9 to 12, that is, when the mastic resin liquid is 1.0%, it is more preferable to add nano-type lactic acid bacteria than to the mastic resin liquid and the mastic essential oil alone.・ It was found that the number of bacteria in P. gulae was somewhat decreasing. However, unlike Examples 1 to 8, in which the concentration of the mastic resin solution was relatively high, it was found that the decrease in the number of bacteria was slow or almost constant.

  Next, Table 4 will be described. Table 4 shows Examples 13 to 16, that is, P. gulae when the mastic resin solution was fixed at 0.5% and the variations of the mastic essential oil and the nano-type lactic acid bacteria were respectively changed. ) Count of bacteria. In addition, about the number of bacteria, like Table 1, Table 2, and Table 3, it converts into the common logarithm so that the digit number of the number of bacteria may become clear.

  In Comparative Examples 9 and 10, as the time passed, the number of bacteria decreased by an order of magnitude or almost constant, that is, the number did not change much, whereas Example 13 with only 0.5% mastic resin solution. In Example 14 using 0.5% mastic resin solution and 0.03% mastic essential oil, the number of P. gulae bacteria was slightly the same as in Comparative Examples 9 and 10. Only a decrease was seen. In addition, Example 15 using 0.5% mastic resin solution and 0.01% nano-type lactic acid bacteria and 0.5% mastic resin solution, 0.03% mastic essential oil and 0.01% nano-type lactic acid bacteria The used Example 16 also had almost the same result as Example 13 and Example 14.

  Therefore, in Examples 13 to 16, that is, when the mastic resin liquid is 0.5%, it is more preferable to add the nano-type lactic acid bacteria than to the mastic resin liquid and the mastic essential oil alone.・ It was found that the number of bacteria in P. gulae was somewhat decreasing. However, unlike Examples 1 to 8, in which the concentration of the mastic resin solution was relatively high, it was found that the decrease in the number of bacteria was slow or almost constant.

  From the above, in this embodiment, only Porphyromonas gurae (P. gulae) is targeted, and other dogs or cats have periodontal disease bacteria (for example, Porphyromonas. Salivosa), etc. ) Shows antibacterial (bactericidal) properties, and there is room for study, and there is room for study of fine conditions (for example, in the In Vivo scale), but at least in the test tube (In Vitro) scale. The antibacterial action and effect of P. gulae of mastic resin, mastic essential oil and / or nano-type lactic acid bacteria, which are constituent elements of the oral composition for animals according to the invention, were sufficiently shown Think of things.

[Production Example] Production of Animal Oral Composition According to the Present Invention Based on the knowledge of Example 8, an animal oral composition (gel paste) according to the present invention was produced. Incidentally, the method for producing the composition was performed in a conventional manner. The composition ratio (% by weight) of each component is as shown in Table 5 below. The total amount of the oral composition was 25 kg.

  The antibacterial action and effect of Porphyromonas grae (P. gulae) related to the oral composition for animals produced with the above-mentioned preparation amount are under intensive study, but at least the test tube (In Vitro) scale Now, let me mention that the test results similar to those in the above-mentioned examples are obtained. In addition, about the composition for oral cavity for animals of the gel paste manufactured by this manufacture example, the form applied to the tooth | gear and gum of an animal (dog, cat) by immersing in a toothbrush or a cotton swab is taken.

  Further, the above production example (preparation amount) is an example, and other components can be appropriately changed as long as the configurations of mastic resin (resin liquid) and mastic essential oil and / or nano-type lactic acid bacteria are observed. .

  As described above, various examples of the oral composition for animals according to the present invention have been described. However, the present invention is not limited to these examples, and various examples can be made without departing from the scope described in the claims and the above embodiments. Embodiments are possible.

In the above-described embodiments and examples, the animal oral composition of the present invention according to the present invention has been mentioned by taking a dentifrice as an example. In the animal oral composition of the present invention, a mastic resin is used. In addition, since the essential oil and / or nano-type lactic acid bacteria are used, it can be applied as an antibacterial agent for animals and a preventive agent for infectious diseases (for example, against gastrointestinal parasitic bacteria).

By the way, prevention of dental caries and periodontal disease is indispensable also in non-human animals, especially pets (pets) such as dogs and cats. In pet animals, like humans, chemical treatment is performed by mechanical plaque control using a toothbrush performed by an owner or the like, and mouth washing using a periodontal disease preventive or therapeutic agent for animals. In addition, treatments with pet foods and chewing gums mixed with these therapeutic agents, medications, and preventive treatments by vaccine administration are performed. By the way, although it depends on the living environment, the dog, as the causative bacteria that causes cat of periodontal disease, in common with humans, for example Porphyromonas gingivalis (Porphyromona s gingivalis), Prevotella intermedia (Prevotella intermedia) is is there. However, teeth that parasitize dogs and cats, such as Porphyromona s g ulae, Porphyromona s s alivosa, and Odoribacter r enticanis, which are not resident in humans. There are also causative bacteria of peri-disease.

A periodontal disease bacteria causing parasitic on dogs and cats, a prophylactic vaccine against P. Gurae (Porphyromona s g ulae) or the like is disclosed, for example, in Japanese Patent No. 4099213 (Patent Document 4). Further, as an oral composition for P. Gurae (Porphyromona s g ulae), etc., the oral composition from tomorrow leaf extract is disclosed in JP 2015-67539 (Patent Document 5).

However, in Patent Documents 1, 2 and 3, only directed to a human, for example, in P. gingivalis (Porphyromona s gingivalis) shows beneficial effects, Porphyromonas Gurae (Porphyromona s g ulae), Descriptions and indications showing such effects on periodontal disease-causing bacteria that parasitize dogs and cats, such as Porphyromonas s s alivosa and Odoribacter r denticanis There is no.

However, in Patent Document 5, for Porphyromonas Gurae (Porphyromona s g ulae), only tomorrow leaf extract is that the active ingredient. And it was mentioned above that there is a description of the use of mastic, but it is only used as a fragrance and is a causative agent of periodontal disease that parasitizes dogs and cats (especially Porphyromona s g ulae) On the other hand, there is no description or suggestion that mastic is effective.

In view of the above circumstances, the present invention can reduce the manufacturing cost by using a mastic resin and / or mastic essential oil, and in particular a periodontal disease-related bacterium (especially porphyro) peculiar to a pet or dog or cat. An object of the present invention is to provide an oral composition for animals which has an effect on Monphys glae (Porphyromona s g ulae).

In addition, the above object of the animal oral composition according to the present invention is to use the mastic resin as a mastic resin solution having a concentration of 5 to 60%, or the mastic resin solution is a solvent. Solvents for dissolving the mastic resin as well as ethanol, glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglycerides (8 to 18 carbon atoms for fatty acid-derived moieties) tri (caprylic acid) / Glyceryl capric acid, fatty acid monoglyceride (8-18 carbon atoms for fatty acid-derived moieties), glyceryl monocaprate, fatty acid ester (8-18 carbon atoms for fatty acid-derived moieties), isopropyl myristate, ethyl isooctanoate, myristine Octyldodecyl acid, higher alcohol (carbon number -22), oleyl alcohol, sorbitan fatty acid (8 to 18 carbon atoms for fatty acid-derived parts) ester, or sucrose fatty acid ester (8 to 18 carbon atoms for fatty acid-derived parts) Or the content of the mastic resin liquid is 0.1 to 50%, or further contains mastic essential oil as an active ingredient, or the content of the mastic essential oil is 0. It is 01 to 1.0%, or further contains a lactic acid bacterium whose mode value in the particle size distribution is 1.0 μm or less as an active ingredient, or the lactic acid bacterium is at least one of Lactobacillus bacteria Or the Lactobacillus bacteria are dead or When the strain of the lactic acid bacterium is Lactobacillus brevis strain BP-4693, or the content of the lactic acid bacterium is 0.01 to 1.0%, or the target animal is a dog or a cat Or by the fact that the periodontal fungus is Porphyromona s g ulae.

According to the composition for oral cavity for animals according to the present invention, the use of a mastic resin and / or mastic essential oil can reduce the production cost, and in particular, it relates to periodontal diseases peculiar to pets such as dogs and cats. It has been shown to act on bacteria (especially Porphyromona s g ulae).

First, the mastic resin will be described. Mastic resin, in the oral composition for animals according to the present invention is an important component which exhibits antibacterial activity against periodontal disease-related bacteria (particularly Porphyromonas Gurae (Porphyromona s g ulae)). As described above, the mastic resin is obtained by naturally drying mastic sap. Incidentally, the time for natural drying is not particularly limited as long as it is one day or longer.

In addition, what is necessary is just to make it become a homogeneous solution with respect to a solvent, when using a mastic resin for the composition for oral cavity for animals which concerns on this invention. Hereinafter, this homogeneous solution is referred to as “mastic resin liquid”. The concentration of the mastic resin liquid is desirably 5 to 60%. Incidentally, when the concentration is 5% or less, an antibacterial effect against Porphyromona s gulae cannot be obtained, and when the concentration is 60% or more, a heterogeneous solution is obtained. The bactericidal effect against Porphyromonas glae is also less than when it is less than 5%.

The content of the mastic resin solution is preferably 0.1 to 50% with respect to the total amount of the oral composition for animals according to the present invention. By the way, when converted as mastic resin itself, if the content of the mastic resin liquid is 0.1% or less, the bactericidal effect on Porphyromona s g ulae is reduced or the bactericidal effect thereof Is not shown. In addition, if the content of the mastic resin liquid is 50% or more, there is a concern that even if the bactericidal effect against Porphyromonas grae is sufficient, the tissue around the affected area in the pet causes some kind of inflammation or allergic reaction. There, and in some cases there is a possibility to lower the bactericidal effect against P. Gurae than in this concentration range (Porphyromona s g ulae).

The content of the mastic essential oil is desirably 0.01 to 1.0% with respect to the total amount of the oral composition for animals according to the present invention. If the content of the mastic essential oil is 1.0% or more, the tissue around the affected area in the pet may cause some inflammation or allergic reaction as in the case of the mastic resin liquid, and in some cases May reduce the bactericidal effect on Porphyromona s g ulae. Incidentally, for the mastic essential oil, even without containing the oral composition for animals according to the present invention, i.e., shows a bactericidal effect against P. Gurae (Porphyromona s g ulae) be only a mastic resin, containing If this is done, a better bactericidal effect can be obtained. In addition, the addition of mastic essential oil plays a role in preventing bad breath. In addition, it is because a bad breath prevention effect is not shown as content of mastic essential oil is 0.01% or less.

And the composition for oral cavity for animals which concerns on this invention is materialized by containing the lactic acid bacteria whose mode value in a particle size distribution is 1.0 micrometer or less as an active ingredient further. The “mode value in the particle size distribution” referred to here is a value serving as an index representing the size (body length) of the bacteria, and the relative frequency in the particle size distribution when the particle diameter (body length) of the cells is measured. The maximum particle size. In other words, when “mode is 1.0 μm or less”, the length of the microbial cell is in the range of 0.1 to 5 μm. Incidentally, the length of the bacterial cell can be measured by a known technique such as an electron microscope. If the mode is at 1.0μm or more, with respect to P. Gurae (Porphyromona s g ulae), shown to indicate the life-and-death effects, since the capture numbers for Said sub fungi suddenly decreases, 1. It is desirable to use it at 0 μm or less. In addition, what is necessary is just to prepare about the lactic acid bacteria used by this invention by a well-known technique (for example, refer international patent publication 2009/157073).

Moreover, it is preferable to contain the said lactic acid bacteria 0.01 to 1.0% with respect to the whole quantity of this oral composition for animals in the oral composition for animals which concerns on this invention. If it is less than 0.01%, lactic acid bacteria, the effect of life-and-death does not exert Porphyromonas Gurae (Porphyromona s g ulae). Moreover, when it is 1.0% or more, the uptake number of the bacteria is affected.

Further, in the same formulation conditions as oral composition for animals of the present invention can be further and prophylactic agent for periodontal disease and bad breath preventive agents for animals for animals.

Papaya extract is an extract derived from natural papaya fruit. It is an extract obtained by crushing the natural papaya fruit and immersing it in a solvent such as ethanol. The papaya fruit is still blue even if it is ripe. It may be in an incomplete state. This papaya extract plays a role as a wetting agent, can keep the moisture in the oral cavity, and particularly unripe papaya is rich in papain enzymes. The papain enzyme is easily removed plaque in between the tooth surface and tooth and gum, the effect of Porphyromonas Gurae the (Porphyromona s g ulae) is vital by lactobacilli is further exhibited. Although the compounding quantity of this papaya extract is not specifically limited, 0.005%-10% are desirable with respect to the whole quantity of the composition for oral cavity which concerns on this invention. If it is less than 0.005% not exhibited the effect described above, there is a possibility that the effect wanes to become excessive than 10%, the lactic acid bacteria of P. Gurae (Porphyromona s g ulae).

On the other hand, chitosan is obtained by boiling chitin obtained from crustacean exoskeletons such as crabs and shrimps by boiling treatment with strong alkali or the like. Since it is a polysaccharide, it may be used as a binder, but it also has an effect of showing an antibacterial agent and a tooth surface coating action. Moreover, the above-mentioned lactic acid bacteria or papain enzyme can be kept on the tooth surface for a longer time. Thereby, the effect of killing and activating Porphyromona s g ulae is more exhibited. Although the compounding quantity of this papaya extract is not specifically limited, 0.005%-10% are desirable with respect to the whole quantity of the composition for oral cavity which concerns on this invention. If it is less than 0.005% not exhibited the effect described above, there is a possibility that the effect wanes to become excessive than 10%, the lactic acid bacteria of P. Gurae (Porphyromona s g ulae).

Furthermore, you may mix | blend chitosan and a papaya extract simultaneously. Thus chitosan papain enzyme and lactic acid bacteria can be lengthened the time to stay between the tooth surface or tooth and gum, sterilization effect by the chitosan mate, is vital Porphyomonas Gurae (Porphyromona s g ulae) effect Is more effective. The blending amount in this case is not particularly limited, but 0.005% to 10% is preferable for each of chitosan and papaya extract. If it is less than 0.005% not exhibited the effect described above, there is a possibility that the effect wanes to become excessive than 10%, the lactic acid bacteria of P. Gurae (Porphyromona s g ulae).

In addition, regarding the oral composition for animals of the present invention, various aspects have been described for Porphyromona s gulae, but periodontals that are resident in mammals other than humans have been described. It seems to be effective against pathogenic fungi such as Porphyromonas s alivosa and Odoribacter r denticanis.

In order to support the above embodiment of the composition for oral cavity according to the present invention, examples will be further described. Examples described here include mastic resin, mastic essential oil, which are constituents of the composition for oral cavity for animals according to the present invention, and lactic acid bacteria whose mode value in particle size distribution is 1.0 μm or less (hereinafter referred to as the present invention). In the examples, periodontal disease bacteria of “nano-type lactic acid bacteria” (in this example, Porphyromonas gulae; hereinafter referred to as “P. gulae” in this example) ) The interaction effect of was investigated.

After completion of the cultivation, the culture broth was 10 minutes pressurized Netsusho sense at 80 ° C., the cells were washed with PBS (phosphate buffer), an excipient and 4 times the amount of dextrin by weight is relative to the cell As a sample, a sample was prepared by lyophilization after dispersing with a mixer, and this was again suspended in PBS so that the cell concentration was 10 mg / mL. In addition, what was hold | maintained at pH 6.5 at the time of a process process was made into the nano type | mold lactic acid bacteria (brevis bacteria) used by a present Example. Furthermore, the nano-type lactic acid bacteria were heat-treated to make dead bacteria.

From the above, in this example, only Porphyromonas gurae (P. gulae) is the target, periodontal disease bacteria peculiar to other dogs or cats (for example, Porphyromonas s s alivosa) , Whether it exhibits antibacterial (bactericidal) properties such as Porphyromonas macacae) , there is room for examination, and there is room for examination of fine conditions (for example, in the In Vivo scale), but at least On the test tube (In Vitro) scale, P. gulae of mastic resin, mastic essential oil and / or nano-type lactic acid bacteria, which are constituents of the oral composition for animals according to the present invention It is thought that the antibacterial action and the effect were sufficiently shown.

Claims (15)

  A veterinary composition for animals which shows a bactericidal effect against periodontal disease bacteria, and contains a mastic resin as an active ingredient.   The veterinary composition for animals according to claim 1, wherein the mastic resin is used as a mastic resin solution having a concentration of 5 to 60%.   The mastic resin solution is dissolved in a solvent, and the solvent for dissolving the mastic resin is ethanol, glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglyceride 8-18) Tri (caprylic acid / capric acid) glyceryl, fatty acid monoglyceride (8-18 carbon atoms for fatty acid-derived moieties), glyceryl monocaprate, fatty acid ester (8-18 carbon atoms for fatty acid-derived moieties), myristic Isopropyl acid, ethyl isooctanoate, octyldodecyl myristate, higher alcohol (8 to 22 carbon atoms), oleyl alcohol, sorbitan fatty acid (8 to 18 carbon atoms for fatty acid-derived part) ester, or sucrose fatty acid ester (fatty acid-derived part For oral composition for animals according to claim 2 which is selected from any one of several 8-18) atoms.   The composition for oral cavity for animals according to claim 2 or 3, wherein the content of the mastic resin liquid is 0.1 to 50%.   The composition for oral cavity for animals according to any one of claims 1 to 4, further comprising mastic essential oil as an active ingredient.   The veterinary composition for animals according to claim 5, wherein the content of the mastic essential oil is 0.01 to 1.0%.   Furthermore, the composition for oral cavity for animals of any one of Claims 1 thru | or 6 which contains the lactic acid bacteria whose mode value in a particle size distribution is 1.0 micrometer or less as an active ingredient.   The oral composition for animals according to claim 7, wherein the lactic acid bacterium is selected from at least one of bacteria belonging to the genus Lactobacillus.   The composition for oral cavity for animals according to claim 8, wherein the Lactobacillus genus bacteria is killed.   The animal oral composition according to any one of claims 7 to 9, wherein the strain of lactic acid bacteria is Lactobacillus brevis strain BP-4693.   The composition for oral cavity for animals according to any one of claims 6 to 10, wherein the content of the lactic acid bacteria is 0.01 to 1.0%.   The animal composition for oral cavity according to any one of claims 1 to 11, wherein the target animal is a dog or a cat.   The veterinary composition for animals according to any one of claims 1 to 12, wherein the periodontal disease bacteria is Porphyromonas. Gulae.   An agent for preventing periodontal disease for animals using the oral composition for animals according to any one of claims 1 to 13. An animal's halitosis preventive agent using the animal oral composition according to any one of claims 1 to 13.